Elective clinical target volumes for conformal therapy in anorectal cancer: a radiation therapy oncology group consensus panel contouring atlas.

PURPOSE To develop a Radiation Therapy Oncology Group (RTOG) atlas of the elective clinical target volume (CTV) definitions to be used for planning pelvic intensity-modulated radiotherapy (IMRT) for anal and rectal cancers. METHODS AND MATERIALS The Gastrointestinal Committee of the RTOG established a task group (the nine physician co-authors) to develop this atlas. They responded to a questionnaire concerning three elective CTVs (CTVA: internal iliac, presacral, and perirectal nodal regions for both anal and rectal case planning; CTVB: external iliac nodal region for anal case planning and for selected rectal cases; CTVC: inguinal nodal region for anal case planning and for select rectal cases), and to outline these areas on individual computed tomographic images. The imaging files were shared via the Advanced Technology Consortium. A program developed by one of the co-authors (I.E.N.) used binomial maximum-likelihood estimates to generate a 95% group consensus contour. The computer-estimated consensus contours were then reviewed by the group and modified to provide a final contouring consensus atlas. RESULTS The panel achieved consensus CTV definitions to be used as guidelines for the adjuvant therapy of rectal cancer and definitive therapy for anal cancer. The most important difference from similar atlases for gynecologic or genitourinary cancer is mesorectal coverage. Detailed target volume contouring guidelines and images are discussed. CONCLUSION This report serves as a template for the definition of the elective CTVs to be used in IMRT planning for anal and rectal cancers, as part of prospective RTOG trials.

[1]  E. Sigurdson,et al.  Phase I trial of preoperative hypofractionated intensity-modulated radiotherapy with incorporated boost and oral capecitabine in locally advanced rectal cancer. , 2007, International journal of radiation oncology, biology, physics.

[2]  J. Tepper,et al.  Risk of Pelvic Fractures in Older Women Following Pelvic Irradiation , 2005, Journal of the American Medical Association (JAMA).

[3]  P. Bendahl,et al.  Dose-volume relationships between enteritis and irradiated bowel volumes during 5-fluorouracil and oxaliplatin based chemoradiotherapy in locally advanced rectal cancer , 2007, Acta oncologica.

[4]  M M Kligerman,et al.  A prospective study of treatment techniques to minimize the volume of pelvic small bowel with reduction of acute and late effects associated with pelvic irradiation. , 1986, International journal of radiation oncology, biology, physics.

[5]  Peter Smeets,et al.  Clinical implementation of intensity-modulated arc therapy (IMAT) for rectal cancer. , 2004, International journal of radiation oncology, biology, physics.

[6]  Josef Korinek,et al.  Proceedings of the American Society of Clinical Oncology , 1982 .

[7]  A. Markoe,et al.  Dose escalation in chemoradiation for anal cancer: preliminary results of RTOG 92-08. , 1996, The cancer journal from Scientific American.

[8]  Charles R. Thomas,et al.  Fluorouracil, mitomycin, and radiotherapy vs fluorouracil, cisplatin, and radiotherapy for carcinoma of the anal canal: a randomized controlled trial. , 2008, JAMA.

[9]  R. Drzymala,et al.  Technical aspects of image-based treatment planning of rectal carcinoma. , 2003, Seminars in radiation oncology.

[10]  J. R. Landis,et al.  The measurement of observer agreement for categorical data. , 1977, Biometrics.

[11]  D. Yan,et al.  The variability of the clinical target volume for rectal cancer due to internal organ motion during adjuvant treatment. , 2002, International journal of radiation oncology, biology, physics.

[12]  D. Dearnaley,et al.  Intensity-modulated radiotherapy in patients with locally advanced rectal cancer reduces volume of bowel treated to high dose levels. , 2006, International journal of radiation oncology, biology, physics.

[13]  Yi-Jen Chen,et al.  Organ sparing by conformal avoidance intensity modulated radiation therapy for anal cancer: Dosimetric evaluation of coverage of pelvis and inguinal/femoral nodes , 2005 .

[14]  Rainer Fietkau,et al.  Preoperative versus postoperative chemoradiotherapy for rectal cancer. , 2004, The New England journal of medicine.

[15]  Robert C. Frazier,et al.  The dose-volume realationship of acute small bowel toxicity from concurrent 5-FU-based chemotherapy and radiation therapy for rectal cancer , 2002 .

[16]  L. Tho,et al.  Acute small bowel toxicity and preoperative chemoradiotherapy for rectal cancer: investigating dose-volume relationships and role for inverse planning. , 2006, International journal of radiation oncology, biology, physics.

[17]  Karin Haustermans,et al.  Definition and delineation of the clinical target volume for rectal cancer. , 2006, International journal of radiation oncology, biology, physics.

[18]  J. Roeske,et al.  Concurrent chemotherapy and intensity-modulated radiation therapy for anal canal cancer patients: a multicenter experience. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[19]  S. Lipsitz,et al.  Initial results of a phase II trial of high dose radiation therapy, 5-fluorouracil, and cisplatin for patients with anal cancer (E4292): an Eastern Cooperative Oncology Group study. , 1996, International journal of radiation oncology, biology, physics.

[20]  N. Petrelli,et al.  Role of mitomycin in combination with fluorouracil and radiotherapy, and of salvage chemoradiation in the definitive nonsurgical treatment of epidermoid carcinoma of the anal canal: results of a phase III randomized intergroup study. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[21]  D. Yan,et al.  The dose-volume relationship of acute small bowel toxicity from concurrent 5-FU-based chemotherapy and radiation therapy for rectal cancer. , 2002, International journal of radiation oncology, biology, physics.

[22]  C. Willett,et al.  Randomized phase II trial of preoperative combined modality chemoradiation for distal rectal cancer , 2004 .

[23]  P. Parikh,et al.  Two-year outcomes of RTOG 0529: A phase II evaluation of dose-painted IMRT in combination with 5-fluorouracil and mitomycin-C for the reduction of acute morbidity in carcinoma of the anal canal. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[24]  C. Lemanski,et al.  Optimal organ-sparing intensity-modulated radiation therapy (IMRT) regimen for the treatment of locally advanced anal canal carcinoma: a comparison of conventional and IMRT plans , 2007, Radiation oncology.

[25]  Bernard Leduc,et al.  Preoperative radiotherapy with or without concurrent fluorouracil and leucovorin in T3-4 rectal cancers: results of FFCD 9203. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[26]  W. Grove.  Statistical Methods for Rates and Proportions, 2nd ed , 1981 .

[27]  William M. Wells,et al.  Simultaneous truth and performance level estimation (STAPLE): an algorithm for the validation of image segmentation , 2004, IEEE Transactions on Medical Imaging.

[28]  B. Everitt,et al.  Statistical methods for rates and proportions , 1973 .

[29]  Laurence Collette,et al.  Chemotherapy with preoperative radiotherapy in rectal cancer. , 2006, The New England journal of medicine.

[30]  Ashesh B Jani,et al.  Intensity-modulated radiation therapy (IMRT) in the treatment of anal cancer: toxicity and clinical outcome. , 2005, International journal of radiation oncology, biology, physics.

[31]  Tae Hyun Kim,et al.  Intensity-modulated radiotherapy with a belly board for rectal cancer , 2007, International Journal of Colorectal Disease.

[32]  D. Yan,et al.  The influence of small bowel motion on both a conventional three-field and intensity modulated radiation therapy (IMRT) for rectal cancer. , 2004, Cancer Radiothérapie.